CoChat

Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*

Constance, C., Westphal, S., Chung, N., Lund, M., McCrary Sisk, C., Johnson‐Levonas, A. O., Massaad, R., Allen, C. · 2007 · Diabetes, Obesity and Metabolism
Cited by 40

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aim: This randomized, double‐blind study evaluated the efficacy of switching from atorvastatin (ATV) 10 mg to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg, EZE/SIMVA 10/40 mg or doubling the dose of ATV from 10 to 20 mg in patients with type 2 diabetes (T2D). Methods: Eligible patients had haemoglobin A 1C ≤10%, were aged ≥18 years and were on ATV 10 mg for ≥6 weeks before study entry. After a 4‐week open‐label ATV 10 mg run‐in, patients were randomized to EZE/SIMVA 10/20 mg (n = 220), EZE/SIMVA 10/40 mg (n = 222) or ATV 20 g (n = 219) daily for 6 weeks. Results: Greater (p ≤ 0.001) reductions in low‐density lipoprotein cholesterol (LDL‐C) (the primary end‐point) were achieved by switching to EZE/SIMVA 10/20 mg (26.2%) or 10/40 mg (30.1%) than by doubling the dose of ATV to 20 mg (8.5%). EZE/SIMVA 10/20 mg and 10/40 mg produced greater (p ≤ 0.001) reductions in total cholesterol, non‐high‐density lipoprotein cholesterol (HDL‐C) and apolipoprotein B relative to ATV 20 mg. A reduction (p ≤ 0.050) in C‐reactive protein was observed with EZE/SIMVA 10/40 mg vs. ATV 20 mg. Similar reductions in triglycerides were observed across the three groups, and none of the treatments produced a significant change in HDL‐C. A greater (p ≤ 0.001) proportion of patients achieved LDL‐C <2.5 mmol/l with EZE/SIMVA 10/20 mg (90.5%) and 10/40 mg (87.0%) than with ATV 20 mg (70.4%). Both EZE/SIMVA doses were generally well tolerated, with an overall safety profile similar to ATV 20 mg. Conclusions: EZE/SIMVA 10/20 and 10/40 mg provided greater lipid‐altering efficacy than doubling the dose of ATV from 10 to 20 mg and were well tolerated in patients with T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2007.00725.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 40

Metadata

Authors
Constance, C., Westphal, S., Chung, N., Lund, M., McCrary Sisk, C., Johnson‐Levonas, A. O., Massaad, R., & Allen, C.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2007-04-19
Volume
9
Issue
4
Pages
575-584
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2144790234
Cited by
40
References
6
FWCI
5.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00725.x
The paper
Constance, C., Westphal, S., Chung, N., Lund, M., McCrary Sisk, C., Johnson‐Levonas, A. O., Massaad, R., & Allen, C. (2007). Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00725.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.